Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

185.05 -4.88 (-2.57%)
Streaming Delayed Price Updated: 10:01 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International
Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo... 
Via Benzinga
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
  SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday. 
Via Benzinga
Recap: Krystal Biotech Q3 Earnings
Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with... 
Via Benzinga
Recap: Krystal Biotech Q4 Earnings
Krystal Biotech (NASDAQ:KRYS) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study
The United States Food and Drug Administration (FDA) has accepted Krystal Biotech’ (NASDAQ: KRYS) Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis... 
Via Benzinga
Krystal Biotech Files To Seek Approval For Skin Disease Candidate
Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of... 
Via Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
Krystal Biotech Inc (NASDAQ:KRYS) shares have po... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: 
Via Benzinga
Why Krystal Biotech's Shares Rose More Than 77% This Week
The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease. 
Via The Motley Fool
Why Krystal Biotech Stock Is Retreating Today
A public offering is weighing on the biotech's shares today. 
Via The Motley Fool
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cumberland (NASDAQ:CPIX) share... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67. The U.S. has... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Krystal Biotech (NASDAQ:KRYS) shares moved upwards by 118.21% to $86.87 during Monday's regular session. Krystal Biotech's stock is trading at a volume of... 
Via Benzinga
Stocks Rise as "Fear Gauge" Cools Off
The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff. 
Via Talk Markets
Topics Stocks
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11. The U.S. has the... 
Via Benzinga
Topics Stocks
33 Stocks Moving In Monday's Mid-Day Session
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational... 
Via Benzinga
KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% Today
Krystal Biotech (KRYS) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial of VYJUVEK. 
Via InvestorPlace
Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views
Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also rose, gaining 0.92% to 4,637.03. The U.S.... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Krystal Biotech (NASDAQ: 
Via Benzinga
Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know
Krystal Biotech Inc (NASDAQ: KRYS) has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.